Rani Therapeutics Holdings (RANI) Change in Accured Expenses (2020 - 2026)

Rani Therapeutics Holdings has reported Change in Accured Expenses for 7 years, with the latest figure at -$1.6 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses fell 504.38% year-over-year to -$1.6 million in Q2 2026; TTM through Jun 2026 was $1.8 million, a 727.27% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, up 809.71% from the prior year.
• Change in Accured Expenses was -$1.6 million for Q2 2026 at Rani Therapeutics Holdings, down from $763000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.2 million in Q4 2025, with the low at -$2.2 million in Q4 2023.
• Average Change in Accured Expenses over 5 years is $155166.7, with a median of $306000.0 recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses plunged 693.67% in 2024, then soared 998.96% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$1.8 million in 2022, then decreased by 21.46% to -$2.2 million in 2023, then jumped by 113.33% to $289000.0 in 2024, then jumped by 998.96% to $3.2 million in 2025, then sank by 149.4% to -$1.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.6 million (Q2 2026), $763000.0 (Q1 2026), and $3.2 million (Q4 2025), per Business Quant data.